| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 3.7K | 3.5% | 20.2% |
| Total Income | 3.8K | 3.8% | 18.9% |
| Expenditure | 3.2K | 1.8% | 35.4% |
| PBT | 621.70 | 15.7% | 26.6% |
| Net Profit | 520.18 | 17.0% | 21.1% |
| OPM | 24.92% | 1.20pp | 4.62pp |
| NPM | 13.73% | 1.55pp | 6.87pp |
| EPS | 12.39 | 16.7% | 24.0% |
Mankind Pharma Reports Q2 and H1 Results for FY2025-26, Net Profit Up by 45.89%
06 Nov 2025 · 6 Nov 2025, 04:30 pm
Summary
Mankind Pharma Limited has reported its Q2 and H1 results for the financial year 2025-26. The net profit has seen a significant increase of 45.89%. The report includes the unaudited Standalone and Consolidated Financial Results, which have been approved by the Board of Directors.
Key Highlights
- 1
Q2 and H1 results for FY2025-26 reported
- 2
Net Profit increased by 45.89%
- 3
Unaudited Standalone and Consolidated Financial Results approved by the Board
- 4
Review Report issued by M/s. S. R. Batliboi & Co. LLP and M/s. Bhagi Bhardwaj Gaur & Co.
Informational and educational content only. Not investment advice.